KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) Non Operating Income (2016 - 2026)

AbbVie has reported Non Operating Income over the past 14 years, most recently at -$1.2 billion for Q4 2025.

  • Quarterly Non Operating Income fell 706.67% to -$1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.8 billion through Dec 2025, down 78.8% year-over-year, with the annual reading at -$5.8 billion for FY2025, 78.8% down from the prior year.
  • Non Operating Income was -$1.2 billion for Q4 2025 at AbbVie, down from -$503.0 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $776.0 million in Q1 2022 and troughed at -$2.7 billion in Q2 2021.
  • The 5-year median for Non Operating Income is -$1.2 billion (2024), against an average of -$932.9 million.
  • Year-over-year, Non Operating Income soared 1671.43% in 2022 and then plummeted 1320.0% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$216.0 million in 2021, then tumbled by 835.65% to -$2.0 billion in 2022, then increased by 23.01% to -$1.6 billion in 2023, then soared by 90.36% to -$150.0 million in 2024, then plummeted by 706.67% to -$1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Non Operating Income are -$1.2 billion (Q4 2025), -$503.0 million (Q3 2025), and -$2.6 billion (Q2 2025).